Q2 2022 13F Holders as of 30 Jun 2022
-
Type / Class
-
Equity / ADSs
-
Shares outstanding
-
592,878
-
Total 13F shares
-
333,825
-
Share change
-
+9,042
-
Total reported value
-
$389,000
-
Price per share
-
$1.17
-
Number of holders
-
13
-
Value change
-
-$12,455
-
Number of buys
-
4
-
Number of sells
-
8
Institutional Holders of Scinai Immunotherapeutics Ltd. - ADSs (BVXV) as of Q2 2022
As of 30 Jun 2022,
Scinai Immunotherapeutics Ltd. - ADSs (BVXV) was held by
13 institutional
shareholders
that filed Form 13F with the SEC.
Together, they reported ownership of
333,825 shares.
The largest 10 holders included
ENVESTNET ASSET MANAGEMENT INC, TRUE Private Wealth Advisors, MORGAN STANLEY, CITADEL ADVISORS LLC, RENAISSANCE TECHNOLOGIES LLC, GEODE CAPITAL MANAGEMENT, LLC, SUSQUEHANNA INTERNATIONAL GROUP, LLP, UBS Group AG, CREDIT AGRICOLE S A, and ROYAL BANK OF CANADA.
This page lists
13
institutional shareholders reporting positions in this security
for the Q2 2022 filing period.
| Investor |
Option |
Weight % |
Change % |
Value $ |
* Price
|
Shares |
Share Change |
Activity |
Report Period |
* Reported Price is the price of the security as of the portfolio date. This value is significant in that it is the last known price at which the security was still held.
An asterisk sign (*) next to the price indicates that the price is likely invalid.